Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the efficacy of AZD9291 compared to placebo as measured by disease free survival (DFS)
Critère d'inclusion
- Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy